FewerJobs.

Madrigal Pharmaceuticals Inc jobs

59 matches, filter-driven and evidence-linked.

Reset
24 shown of 59

Benefit evidence

Resolvable source Inferred from posting Unknown provenance
Only verified benefits
  • Medical Science Liaison, Florida South

    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    4 days ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +5
    Unspecified Healthcare From the posting source - Mid From the posting source $195K-$239K From the posting source Equity Inferred from posting 401(k) reported

    Medical Science Liaison, Florida South Miami, FL Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. MEDICAL SCIENCE LIAISON (MSL), MEDICAL AFFAIRS Field-Based Medical role reporting to a regional Field Director. The Madrigal MSL will build scientific partnerships with Healthcare Professionals and decision makers using evidence-based science and non-promotional scientific exchange. The MSL will serve as a point of contact for the latest scientific and clinical information regarding Madrigal's novel NASH research program to thought leaders, academic centers, community group practices and regional professional organizations. MSL will report external insights to better understand MASH diagnosis

  • Medical Science Liaison, Great Lakes

    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    4 days ago

    Why we showed this

    Description: "madrigal"Description: "inc"
    +5
    Unspecified Healthcare From the posting source - Mid From the posting source $195K-$239K From the posting source Equity Inferred from posting 401(k) reported

    Medical Science Liaison, Great Lakes Detroit, MI Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. MEDICAL SCIENCE LIAISON (MSL), MEDICAL AFFAIRS Field-Based Medical role reporting to a regional Field Director. The Madrigal MSL will build scientific partnerships with Healthcare Professionals and decision makers using evidence-based science and non-promotional scientific exchange. The MSL will serve as a point of contact for the latest scientific and clinical information regarding Madrigal's novel NASH research program to thought leaders, academic centers, community group practices and regional professional organizations. MSL will report external insights to better understand MASH diagnosis

  • Associate Director, Market Access Analytics

    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    3w ago

    Why we showed this

    Description: "madrigal"Description: "inc"
    +6
    Unspecified Data From the posting source - Director Plus From the posting source $208K-$208K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Associate Director, Market Access Analytics 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director, Market Access Analytics leads payer, formulary, and coverage analytics for Madrigal's Commercial organization, turning access and contracting data into insight that guides Market Access strategy for the MASH portfolio. Reporting to the Senior Director, Market Access, Trade & IDN Analytics, this role owns the payer analytics and reporting agenda - measuring formulary access, coverage, utilization management, and contract performance at national and sub-national levels - and serves as a trusted analytics partner to Managed Markets, Patient

  • Associate Director, Medical Information

    Madrigal Pharmaceuticals Inc - Munich - Germany - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026
    posted 33 days ago

    Why we showed this

    Employer: semantic matchEmployer: "madrigal"
    +4
    Unspecified Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Associate Director, Medical Information Munich - Germany - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. All full-time employees receive equity, which reinforces our ownership culture and offers meaningful opportunity for our employees to share in the success they help create. By aligning individual and company performance, we empower employees to think like owners, giving them a stake in the organization. Full-time employees are also eligible for comprehensive benefits, including flexible paid time off, medical, dental, vision and life/disability insurance, and 401(k) offerings (i.e., traditional, Roth, and employer match) in accordance with applicable

  • Senior Manager – Accounting

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    2w ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +5
    Unspecified Finance From the posting source - Senior From the posting source $139K-$169K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Senior Manager – Accounting PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. We are seeking a Senior Manager, Accounting to join our finance team. The ideal candidate will have a strong fundamental understanding of U.S. GAAP and experience managing general ledger accounting and financial close activities. Experience within the pharmaceutical, biotechnology, or life sciences industry is strongly preferred. The Senior Manager, Accounting will play a key role in overseeing the monthly, quarterly, and annual close process and ensuring the accuracy, completeness, and integrity of the Company's financial records. This

  • Associate Director, Trial Master File Operations

    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    1w ago

    Why we showed this

    Employer: semantic matchEmployer: "madrigal"
    +4
    Unspecified Other - Director Plus From the posting source $179K-$206K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Associate Director, Trial Master File Operations 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director (AD) TMF Operations will be responsible for leading day-to-day TMF operational strategy, oversight, inspection readiness, sponsor QC oversight, metrics management, issue escalation, and governance across the TMF operating model. This role will ensure that TMF processes are consistently executed, inspection-ready, and aligned with regulatory expectations, internal standards, study needs, and sponsor oversight obligations. This individual will serve as the primary business owner for TMF operational quality and will manage FSP resources supporting TMF activities. The

  • Key Account Director - Heartland

    Madrigal Pharmaceuticals Inc - Kansas City, MO
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    2w ago

    Why we showed this

    Description: "madrigal"Description: "inc"
    +5
    Unspecified Sales From the posting source - Director Plus From the posting source $217K-$217K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Key Account Director - Heartland Kansas City, MO Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. As a Key Account Director (KAD) at Madrigal, you will play a vital role in ensuring access to Rezdiffra within assigned regional Integrated Delivery Networks (IDNs) and HCP Super Groups. Working collaboratively across the matrix team, you will execute effective pull-through programs to drive the adoption of Rezdiffra and strengthen relationships with key stakeholders. Position Responsibilities: Represent Madrigal with Integrated Delivery Systems and large HCP Super Groups, engaging with C-suite executives, pharmacy directors, and medical directors within the

  • Medical Science Liaison, North Atlantic

    Madrigal Pharmaceuticals Inc - CT - Connecticut - Field
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    3 days ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +5
    Unspecified Healthcare From the posting source - Mid From the posting source $195K-$239K From the posting source Equity Inferred from posting 401(k) reported

    Medical Science Liaison, North Atlantic CT - Connecticut - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. MEDICAL SCIENCE LIAISON (MSL), MEDICAL AFFAIRS Field-Based Medical role reporting to a regional Field Director. The Madrigal MSL will build scientific partnerships with Healthcare Professionals and decision makers using evidence-based science and non-promotional scientific exchange. The MSL will serve as a point of contact for the latest scientific and clinical information regarding Madrigal's novel NASH research program to thought leaders, academic centers, community group practices and regional professional organizations. MSL will report external insights to better

  • VP, Commercial & Medical Affairs IT Business Partner

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    1w ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +6
    Unspecified Healthcare From the posting source - Director Plus From the posting source $295K-$295K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    VP, Commercial & Medical Affairs IT Business Partner PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Vice President, Commercial & Medical Affairs IT Business Partner will lead Madrigal's Commercial and Medical Affairs IT Business Partnership, supporting the company's global Commercial and Medical Affairs organizations. This role will serve as the senior IT partner to the Commercial and Medical Affairs executive leadership teams, translating functional strategy into technology roadmaps, portfolio priorities, operating capabilities, and delivery outcomes. As Madrigal continues to scale as a commercial-stage company, the technology needs across

  • Associate Director, Data Enablement

    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    5 days ago

    Why we showed this

    Description: "madrigal"Description: "inc"
    +6
    Unspecified Other - Staff Plus From the posting source $180K-$220K From the posting source Equity Inferred from posting 401(k) reported

    Associate Director, Data Enablement 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director, Data Enablement is a client-facing data partner for Madrigal's Commercial organization, ensuring strategic and operational data needs are met across requirements, integration, acquisition, and day-to-day operations. Reporting to the Director, Data Enablement, this role spans all commercial data domains - Market Access, Trade, Patient Services (MPS), Marketing, and Sales - translating business needs into governed, analytics-ready data and safeguarding the continuity of the data that powers Commercial decision-making. This is a hands-on role for someone fluent in

  • Head of Market Access, Italy

    Madrigal Pharmaceuticals Inc - Milano - Italy - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026
    posted 33 days ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +5
    Unspecified Other - Senior From the posting source Salary not disclosed Equity Inferred from posting 401(k) reported

    Head of Market Access, Italy Milano - Italy - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Head of Market Access - Italy Location: Milan Summary The Head of Market Access, reporting to the VP, General Manager, will play a pivotal leadership role in ensuring Italian patients gain timely and sustainable access to Madrigal's innovative therapies. This role defines and executes the national market access and pricing strategy, drives engagement with Italian authorities and payers, and shapes the local access environment in alignment with Madrigal's global access vision. Working collaboratively with Medical, Regulatory, HEOR, Commercial, and Regional and Global Access colleagues, this leader will help translate science into access, ensuring the value of innovation is recognized across the Italian healthcare system. Acting as an enterprise leader, the incumbent will demonstrate patient focus in every decision, act with an owner mindset, champion innovation, and foster collaboration to drive impact and advance Madrigal's purpose of leading the fight against

  • Associate Director, Orchestration Analytics & Products

    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    3w ago

    Why we showed this

    Employer: semantic matchEmployer: "madrigal"
    +4
    Unspecified Data From the posting source - Director Plus From the posting source $171K-$209K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Associate Director, Orchestration Analytics & Products 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director, Orchestration Analytics & Products leads the strategy, design, and activation of analytics-enabled orchestration products across HCP engagement and Patient Services. Reporting to the Senior Director, Advanced Analytics Products, this role translates Commercial business needs into scalable products that use data, analytics, AI, and business rules to improve how decisions are made and activated across customer and patient journeys. Serving as the connective product leader across Commercial functions, Advanced Analytics, Data Enablement, and IT, the Associate

  • Area Business Manager, Chicago North

    Madrigal Pharmaceuticals Inc - IL - Illinois - Field
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    1w ago

    Why we showed this

    Description: "madrigal"Description: "inc"
    +5
    Unspecified Other - Mid From the posting source $158K-$192K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Area Business Manager, Chicago North IL - Illinois - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. In this role, the Area Business Manager (ABM) will develop the territory business plan to achieve/exceed business and sales goals. You will work closely with your team and others across the organization to execute and deliver sales results that contribute to the overall performance, culture, and success of the organization. The Area Business Manager will play a pivotal role in introducing Madrigal and our potential groundbreaking first-to-market product addressing a significant patient unmet need. As an

  • Vice President, Clinical Development Program Leader

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026
    posted 33 days ago

    Why we showed this

    Description: "madrigal"Description: "pharmaceuticals"
    +7
    Unspecified Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Vice President, Clinical Development Program Leader PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Vice President, Clinical Development Program Leader Company Background Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. The company's medication, Rezdiffra (resmetirom), is the first and only FDA and European Commission-approved treatment for MASH with moderate to advanced fibrosis. Madrigal's pipeline includes ongoing Phase 3 trials and new assets in early development. Role Overview The Vice President, Clinical Development

  • Director, Drug Product Small Molecule SME

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    2w ago

    Why we showed this

    Description: "madrigal"Description: "inc"
    +6
    Unspecified Other - Director Plus From the posting source $204K-$250K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Director, Drug Product Small Molecule SME PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Position Summary The Director Drug Product SME is an experienced scientific and technical leader, accountable for defining and driving the CMC drug product development strategy for Madrigal's small molecule portfolio. This role leads drug product formulation and process development, ensuring preclinical and clinical studies are supported with phase-appropriate quality investigational medicinal product, delivered on time and guided by scientific rigor, risk assessment and data-driven decision-making. The Director is accountable for leading at least one cross-functional

  • Senior Director, Data Operations & Enablement

    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    3w ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +6
    Unspecified Other - Director Plus From the posting source $312K-$312K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Senior Director, Data Operations & Enablement 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Senior Director, Data Operations & Enablement is the senior operator and point of contact for Madrigal's commercial data ecosystem - accountable for the reliability, quality, integration, and scalability of the data that powers the entire Commercial organization. Reporting to the Executive Director, Commercial Data Strategy & Analytics, this leader owns the operations of the end-to-end commercial data supply chain: source integration, data quality, master data management, data products, and business intelligence. The role turns a growing collection

  • Manager, Biostatistics

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 33 days ago

    Why we showed this

    Description: "pharmaceuticals"Description: "inc"
    +7
    Unspecified Data From the posting source - Mid From the posting source $149K-$181K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Manager, Biostatistics PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Manager, Biostatistics is an early-career individual contributor that will contribute to multiple biostatistical activities for Madrigal Pharmaceuticals, covering all phases of clinical development and post-marketing efforts. This role will support the translation of organizational objectives into statistical deliverables, contribute to the execution of statistical strategies, and deliver high-quality analytical outputs. This role will collaborate with other biostatisticians, programmers and cross-functional team members either within the company or at a CRO partner to ensure that Madrigal's analytical objectives are

  • Thought Leader Liaison - Great Lakes

    Madrigal Pharmaceuticals Inc - MI - Michigan - Field
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 33 days ago

    Why we showed this

    Description: "pharmaceuticals"Description: "madrigal"
    +6
    Unspecified Other - Mid From the posting source $215K-$263K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Thought Leader Liaison - Great Lakes MI - Michigan - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Thought Leader Liaisons (TLL) The Thought Leader Liaison (TLL) at Madrigal Pharmaceuticals is a commercial role as a dynamic leader with deep customer knowledge and passion to exceed organizational success. This position focuses on building and fostering strong partnerships with Thought Leaders in academic and clinical medicine to support the launch of Resmetirom, a ground-breaking therapy for Metabolic Associated Steatohepatitis (MASH). As a TLL, you'll play a key role in executing brand and disease-state strategies

  • Vice President, IT Resilience & Trust

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    1w ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +5
    Unspecified Other - Director Plus From the posting source $295K-$295K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Vice President, IT Resilience & Trust PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Vice President, IT Resilience & Trust is a strategic and operational technology executive responsible for ensuring Madrigal's technology environment is reliable, resilient, secure, compliant, and able to scale with the business. As Madrigal continues to grow, expand internationally, and adopt new technologies at increasing speed, the technology foundation supporting the company is becoming more complex, interconnected, and critical to business performance. This leader will bring together Infrastructure & Reliability, Cybersecurity, and Technology Compliance under

  • Area Business Manager, Orange County South

    Madrigal Pharmaceuticals Inc - CA - California - Field
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    2w ago

    Why we showed this

    Description: "madrigal"Description: "inc"
    +5
    Unspecified Other - Mid From the posting source $158K-$192K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Area Business Manager, Orange County South CA - California - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. In this role, the Area Business Manager (ABM) will develop the territory business plan to achieve/exceed business and sales goals. You will work closely with your team and others across the organization to execute and deliver sales results that contribute to the overall performance, culture, and success of the organization. The Area Business Manager will play a pivotal role in introducing Madrigal and our potential groundbreaking first-to-market product addressing a significant patient unmet need. As

  • Senior Manager, MSAT Product Knowledge Steward

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 33 days ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +5
    Unspecified Other - Senior From the posting source $156K-$184K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Senior Manager, MSAT Product Knowledge Steward PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Position Summary The Senior Manager, MSAT Product Knowledge Steward is the scientific steward for assigned small-molecule pharmaceutical products, serving as the technical subject matter expert responsible for preserving, integrating, and communicating product knowledge spanning drug substance, drug product and finished goods across the entire product lifecycle-from process development through technology transfer, commercial manufacturing, and post-approval lifecycle management. The ideal candidate is an experienced Process Development scientist who enjoys organizing complex technical knowledge as much as

  • Senior Director Biostatistics

    Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 33 days ago

    Why we showed this

    Description: "pharmaceuticals"Description: "madrigal"
    +6
    Unspecified Data From the posting source - Director Plus From the posting source $264K-$322K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Senior Director Biostatistics PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Senior Director of Biostatistics is an individual contributor that will lead multiple biostatistical activities for Madrigal Pharmaceuticals, covering all phases of clinical development. This role will collaborate with other biostatisticians and programmers either in the company or at a CRO to ensure meeting R&D objectives. The incumbent will translate R&D objectives into relevant work products, establish statistical strategies and ensure quality execution. The position will be a combination of conducting complex statistical analyses, developing SAPs and contributing

  • Senior Manager, GCP Quality Assurance

    Madrigal Pharmaceuticals Inc - PA - Pennsylvania – Remote
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 33 days ago

    Why we showed this

    Description: "inc"Description: "madrigal"
    +5
    Remote From the posting source Other - Senior From the posting source $147K-$180K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Senior Manager, GCP Quality Assurance PA - Pennsylvania – Remote Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Position Summary This position will be responsible for GCP/Clinical Quality Assurance activities. The primary responsibilities will be to ensure quality and compliance of Madrigal-sponsored clinical trials with applicable GCP regulations, ICH GCP guidelines, Madrigal SOPs, and current industry standards and best practices. This position reports into the Senior Director, GCP Quality Key Responsibilities Strategy, Compliance and Oversight May develop, implement, and/or maintain clinical quality systems and processes to ensure compliance with ICH GCP, FDA, EMA, and

  • Thought Leader Liaison- Cleveland/Pittsburgh

    Madrigal Pharmaceuticals Inc - OH - Ohio - Field
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 33 days ago

    Why we showed this

    Description: "pharmaceuticals"Description: "madrigal"
    +6
    Unspecified Other - Mid From the posting source $215K-$263K From the posting source Inferred from posting Mental health support Equity Inferred from posting 401(k) reported

    Thought Leader Liaison- Cleveland/Pittsburgh OH - Ohio - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Thought Leader Liaison (TLL) at Madrigal Pharmaceuticals is a commercial role as a dynamic leader with deep customer knowledge and passion to exceed organizational success. This position focuses on building and fostering strong partnerships with Thought Leaders in academic and clinical medicine to support the launch of Resmetirom, a ground-breaking therapy for Metabolic Associated Steatohepatitis (MASH). As a TLL, you'll play a key role in executing brand and disease-state strategies through impactful Thought Leader engagement, generating

Take this list with you

Download the 59 matching jobs in any format - read offline, archive, or hand to an AI assistant with your resume to find the best fits.

Or email it to me instead

The AI-ready prompt is a pre-written question you can paste into Claude, ChatGPT, Gemini, or Perplexity along with your resume. We never see your resume; this happens in your AI client of choice.

AI agent reading directly? Same data lives at /api/jobs.json?q=Madrigal+Pharmaceuticals+Inc&quality=all. See /llms.txt and /api/openapi.json for the full schema.